[Targeted therapy for cancer: anti-tyrosine kinase receptor agents].

Abstract

The use of drugs to treat cancer based on molecular targets is common fact, especially those targeting kinases that are involved in the cellular signalling pathways. The anti-tyrosine receptor drugs are among the most developed, some of them having already been approved by the FDA and the EMEA for breast cancer, colorectal, lung GIST and renal cancer treatment. Although these drugs are currently focused on a single target, the future challenge is to hit several targets simultaneously, along with combined chemotherapy. Thus we are facing the beginning of a new era in the battle against cancer.

• Authors: Eduardo Díaz-Rubio García
• Journal: Anales de la Real Academia Nacional de Medicina (An R Acad Nac Med (Madr)) Vol. 124 Issue 1 Pg. 171-84; discussion 184-8 ( 2007) ISSN: 0034-0634 [Print] Spain
• Vernacular Title: Nuevas dianas terapéuticas en cáncer: fármacos frente a los receptores de tirosina quinasa.
• PMID: 18069612 (Publication Type: Lecture)

Chemical References

• ErbB Receptors
• Receptor Protein-Tyrosine Kinases
• Receptors, Vascular Endothelial Growth Factor

Topics

• ErbB Receptors (antagonists & inhibitors)
• Humans
• Neoplasms (drug therapy)
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)